The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, experts warned patients were being denied access to personalised cancer care. Cancer… Read More
News round-up for 29 June – 3 July by Bruno Quinney, Content Team at DDW. This week, experts warn patients are being denied access to personalised cancer care. Cancer research is a theme elsewhere, with findings emerging from studies into a CAR T-cell therapy, lung cancer and breast cancer. The… Read More
A new CAR T-cell therapy can target key mutations causing rare blood cancers and leave healthy blood cells unharmed, scientists say. A research effort led by University College London (UCL) and the University of Oxford engineered a CAR T-cell therapy which can reprogramme a patient’s own immune cells… Read More
DDW’s Maria Wallace attended Cancer Research Horizons’ On the Horizon breakfast event to learn more about the latest opportunities and challenges in cancer drug discovery and development. Leading experts from academia, pharma, biotech and investment met in London, UK Thursday 11 June to discuss the potential of in vivo CAR-T therapies to transform the future of… Read More
It is an exciting time in cancer drug discovery. Seven in 10 people now survive their cancer five years or more, up from only half in the mid-70s, according to the American Cancer Society’s 2026 Cancer Statistics. New modalities, like radiopharmaceuticals, alongside new drug targets, like KRAS mutations, are resulting… Read More
Biotechnology companies Circio Holding and Acuitas Therapeutics have entered a technology evaluation agreement for an in vivo CAR-T cell therapy. As part of the agreement, Circio’s circVec circular RNA expression technology will be tested alongside Acuitas’ proprietary T-cell-targeted lipid nanoparticle (LNP) delivery system. The companies aim to assess whether Acuitas’ LNP technology can be deployed to deliver circVec for… Read More
Biotech companies Dispatch Bio and CARsgen Therapeutics have announced a clinical collaboration to develop innovative CAR-T cell therapies. The trial will evaluate DISP-11, an investigational therapy leveraging Dispatch’s Flare platform. This includes DV-10, the company’s novel tumour-specific virus, and CARsgen’s zevorcabtagene autoleucel (zevor-cel), an autologous B-cell maturation… Read More
Biotechnology company Miltenyi Biotec has announced encouraging results from its CAR-T therapy for patients with second-line, relapsed or refractory large B-cell lymphoma. Primary analysis of candidate zamtocabtagene autoleucel (zamto-cel) showed the therapy demonstrated significant and clinically meaningful superiority over chemoimmunotherapy. The candidate was evaluated in the DALY 2-EU trial, conducted… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research into bacterial species and diseases broke new ground. Elsewhere, vaccines could… Read More
News round-up for 17 – 21 November by Bruno Quinney, Content Team at DDW. This week in DDW, research into bacterial species and diseases gets top billing. Elsewhere, vaccines could offer groundbreaking solutions to cervical and lung cancer. The top stories: Medication detrimental to gut microbiome,… Read More
The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to MB-105, a CAR-T cell therapy developed by biotechnology company March Biosciences. The designation was granted based on data from March Bio’s ongoing multi-centre Phase II clinical trial. Preliminary findings from the… Read More
Scientists have successfully used the first bioengineered bone marrow model to carry out cancer research, offering a new method which does not rely on animal models. The breakthrough, made by researchers at the University of Glasgow, represents an important step forward in being able to uncover insights into leukaemia without the… Read More
